FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8140人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839704, encodeId=71d81839e04fe, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂, objectType=article, longId=175621, objectId=98461e5621b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98461e5621b5, replyNumber=0, likeNumber=73, createdTime=2020-03-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98461e5621b5, moduleTitle=FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98461e5621b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839722, encodeId=ab801839e22a5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=益普生宣布FDA批准其A型肉毒杆菌毒素Dysport用于治疗儿童的上肢痉挛, objectType=article, longId=180143, objectId=5d22180143c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d22180143c6, replyNumber=0, likeNumber=63, createdTime=2019-10-06, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d22180143c6, moduleTitle=益普生宣布FDA批准其A型肉毒杆菌毒素Dysport用于治疗儿童的上肢痉挛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d22180143c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839702, encodeId=08501839e028f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Xembify治疗原发性免疫缺陷, objectType=article, longId=174892, objectId=4adf1e489288, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4adf1e489288, replyNumber=0, likeNumber=59, createdTime=2019-07-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4adf1e489288, moduleTitle=FDA批准Xembify治疗原发性免疫缺陷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4adf1e489288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839653, encodeId=18a618396532a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, objectType=article, longId=160532, objectId=d280160532df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d280160532df, replyNumber=0, likeNumber=62, createdTime=2019-06-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d280160532df, moduleTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d280160532df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839723, encodeId=9dc91839e2308, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准利妥昔单抗联合类固醇激素治疗儿童血管炎, objectType=article, longId=180296, objectId=f9a2180296ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9a2180296ef, replyNumber=0, likeNumber=72, createdTime=2020-03-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9a2180296ef, moduleTitle=FDA批准利妥昔单抗联合类固醇激素治疗儿童血管炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9a2180296ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839640, encodeId=f5fb1839640d8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准曲妥珠单抗生物类似物Herzuma（曲妥珠单抗-pkrb）, objectType=article, longId=155932, objectId=d125155932ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d125155932ad, replyNumber=0, likeNumber=125, createdTime=2019-04-19, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d125155932ad, moduleTitle=FDA批准曲妥珠单抗生物类似物Herzuma（曲妥珠单抗-pkrb）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d125155932ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839670, encodeId=15cc18396e0fc, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Hematogenix针对三阴乳腺癌推出获得FDA批准的伴随诊断肿瘤免疫检测, objectType=article, longId=162296, objectId=bc66162296de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc66162296de, replyNumber=0, likeNumber=143, createdTime=2020-02-20, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc66162296de, moduleTitle=Hematogenix针对三阴乳腺癌推出获得FDA批准的伴随诊断肿瘤免疫检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc66162296de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839714, encodeId=ac231839e14dc, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准美国WorldMeds的B型肉毒杆菌MYOBLOC注射治疗慢性流涎, objectType=article, longId=178243, objectId=27d71e824343, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27d71e824343, replyNumber=0, likeNumber=117, createdTime=2020-01-20, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27d71e824343, moduleTitle=FDA批准美国WorldMeds的B型肉毒杆菌MYOBLOC注射治疗慢性流涎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27d71e824343)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839691, encodeId=3aa91839691b8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=移植物抗宿主病治疗的新契机：FDA批准Jakafi用于类固醇难治性急性GVHD, objectType=article, longId=166799, objectId=12a0166e99b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12a0166e99b9, replyNumber=0, likeNumber=73, createdTime=2019-12-30, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12a0166e99b9, moduleTitle=移植物抗宿主病治疗的新契机：FDA批准Jakafi用于类固醇难治性急性GVHD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12a0166e99b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839649, encodeId=1d5918396499f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Lung Cancer：特异性97.9%，敏感性72.1%！吴一龙团队分析三项亚洲队列发现，通过FDA批准的液体活检可以作为肺癌组织检测的有力补充, objectType=article, longId=159080, objectId=b8f715908063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8f715908063, replyNumber=0, likeNumber=66, createdTime=2019-05-17, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8f715908063, moduleTitle=Lung Cancer：特异性97.9%，敏感性72.1%！吴一龙团队分析三项亚洲队列发现，通过FDA批准的液体活检可以作为肺癌组织检测的有力补充, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8f715908063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839659, encodeId=a00f18396595c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准LOTEMAX（氯替泼诺依碳酸盐眼用凝胶）用于治疗眼外科手术后的炎症和疼痛, objectType=article, longId=161243, objectId=e54f16124322, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e54f16124322, replyNumber=0, likeNumber=65, createdTime=2019-10-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e54f16124322, moduleTitle=FDA批准LOTEMAX（氯替泼诺依碳酸盐眼用凝胶）用于治疗眼外科手术后的炎症和疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e54f16124322)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839686, encodeId=eff718396866b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Fragmin（达肝素钠）作为儿童的第一个抗凝剂, objectType=article, longId=166317, objectId=d5d816631e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5d816631e72, replyNumber=0, likeNumber=65, createdTime=2020-02-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5d816631e72, moduleTitle=FDA批准Fragmin（达肝素钠）作为儿童的第一个抗凝剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5d816631e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839641, encodeId=c86718396417c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Amgen的Nplate治疗儿科免疫性血小板减少症, objectType=article, longId=155933, objectId=5a611559332d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a611559332d, replyNumber=0, likeNumber=72, createdTime=2019-03-20, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a611559332d, moduleTitle=FDA批准Amgen的Nplate治疗儿科免疫性血小板减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a611559332d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839658, encodeId=e4721839658be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=百洋制药降糖新产品奈达获得FDA批准上市, objectType=article, longId=161202, objectId=818016120299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=818016120299, replyNumber=0, likeNumber=59, createdTime=2019-03-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=818016120299, moduleTitle=百洋制药降糖新产品奈达获得FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=818016120299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839688, encodeId=971718396889f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=儿童抗凝药获批！美FDA批准达肝素钠注射剂用于儿童, objectType=article, longId=166580, objectId=8eee16658030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eee16658030, replyNumber=0, likeNumber=47, createdTime=2019-11-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eee16658030, moduleTitle=儿童抗凝药获批！美FDA批准达肝素钠注射剂用于儿童, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eee16658030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839662, encodeId=d04418396620e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, objectType=article, longId=161432, objectId=c21f16143225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c21f16143225, replyNumber=0, likeNumber=77, createdTime=2019-03-07, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c21f16143225, moduleTitle=美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c21f16143225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839621, encodeId=e784183962182, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准丁丙诺啡和纳洛酮的新剂量强度, objectType=article, longId=148546, objectId=0ad814854670, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ad814854670, replyNumber=0, likeNumber=91, createdTime=2019-08-20, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ad814854670, moduleTitle=FDA批准丁丙诺啡和纳洛酮的新剂量强度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ad814854670)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839629, encodeId=614d183962956, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=17年来！FDA批准新型心脏支架治疗动脉穿孔, objectType=article, longId=150002, objectId=349c15000268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=349c15000268, replyNumber=0, likeNumber=54, createdTime=2019-06-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=349c15000268, moduleTitle=17年来！FDA批准新型心脏支架治疗动脉穿孔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=349c15000268)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839689, encodeId=c537183968921, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准优时比鼻腔给药癫痫疗法上市, objectType=article, longId=166594, objectId=f63616659477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f63616659477, replyNumber=0, likeNumber=63, createdTime=2019-05-30, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f63616659477, moduleTitle=FDA批准优时比鼻腔给药癫痫疗法上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f63616659477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839656, encodeId=11a7183965656, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=精准医疗推进，FDA批准协同作用胰岛素泵，可构建糖尿病个性化治疗系统！, objectType=article, longId=160957, objectId=3af916095ea8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3af916095ea8, replyNumber=0, likeNumber=81, createdTime=2019-08-11, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3af916095ea8, moduleTitle=精准医疗推进，FDA批准协同作用胰岛素泵，可构建糖尿病个性化治疗系统！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3af916095ea8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Gadavist注射液作为心脏磁共振（MR）成像的造影剂

2020-03-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

益普生宣布FDA批准其A型肉毒杆菌毒素Dysport用于治疗儿童的上肢痉挛

2019-10-06

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Xembify治疗原发性免疫缺陷

2019-07-26

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准新型心血管支持液VBI-1进入II期临床试验

2019-06-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准利妥昔单抗联合类固醇激素治疗儿童血管炎

2020-03-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准曲妥珠单抗生物类似物Herzuma（曲妥珠单抗-pkrb）

2019-04-19

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Hematogenix针对三阴乳腺癌推出获得FDA批准的伴随诊断肿瘤免疫检测

2020-02-20

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准美国WorldMeds的B型肉毒杆菌MYOBLOC注射治疗慢性流涎

2020-01-20

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

移植物抗宿主病治疗的新契机：FDA批准Jakafi用于类固醇难治性急性GVHD

2019-12-30

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Lung Cancer：特异性97.9%，敏感性72.1%！吴一龙团队分析三项亚洲队列发现，通过FDA批准的液体活检可以作为肺癌组织检测的有力补充

2019-05-17

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准LOTEMAX（氯替泼诺依碳酸盐眼用凝胶）用于治疗眼外科手术后的炎症和疼痛

2019-10-06

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Fragmin（达肝素钠）作为儿童的第一个抗凝剂

2020-02-06

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Amgen的Nplate治疗儿科免疫性血小板减少症

2019-03-20

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

百洋制药降糖新产品奈达获得FDA批准上市

2019-03-03

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

儿童抗凝药获批！美FDA批准达肝素钠注射剂用于儿童

2019-11-03

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准新型TREMFYA（guselkumab）制剂治疗成人中度至重度斑块型银屑病

2019-03-07

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准丁丙诺啡和纳洛酮的新剂量强度

2019-08-20

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

17年来！FDA批准新型心脏支架治疗动脉穿孔

2019-06-03

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准优时比鼻腔给药癫痫疗法上市

2019-05-30

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

精准医疗推进，FDA批准协同作用胰岛素泵，可构建糖尿病个性化治疗系统！

2019-08-11

科室
- - 订阅+
  - 更多科室
工具
服务